The prophylactic efficacy of poly(ICLC) ( Poly(ICLC), the stabilized, synthetic, double-stranded polyriboinosinic-polyribocytidylic acid, is an effective in vivo immunomodulator and interferon inducer (2, 7, 9, 14) . In primates and rodents, poly(ICLC) has proved useful in the prophylaxis of several viral infections (1, 3, 5, 8, 11, 12) . Poly(ICLC) confers an antiviral state that persists for several days by stimulation of the immune response (2, 14) and induction of interferon production (7, 8) . Interferon and the cellular immune response are both believed to play a role in altering the pathogenesis of viral infections.
Poly(ICLC), the stabilized, synthetic, double-stranded polyriboinosinic-polyribocytidylic acid, is an effective in vivo immunomodulator and interferon inducer (2, 7, 9, 14) . In primates and rodents, poly(ICLC) has proved useful in the prophylaxis of several viral infections (1, 3, 5, 8, 11, 12) . Poly(ICLC) confers an antiviral state that persists for several days by stimulation of the immune response (2, 14) and induction of interferon production (7, 8) . Interferon and the cellular immune response are both believed to play a role in altering the pathogenesis of viral infections.
The objectives of this study were to identify the optimal prophylactic treatment schedule of poly(ICLC) in Rift Valley fever virus (RVFV)-infected mice, delineate the optimal timing between the first and additional doses of drug, and determine the minimal effective dose as a guide for a possible human study. The efficacy of various poly(ICLC) treatment schedules was also ranked by a statistical model.
MATERIALS AND METHODS
Antiviral compounds. Poly(ICLC) was prepared by the Pharmaceutical Service, College of Pharmacy, University of Iowa, Iowa City. Each milliliter contained 2 mg of poly(ICLC), 1 
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0.- The survival data at day 10 ( Fig. 2) indicated that a single fter challenge.
treatment with 20 p.g of poly(ICLC) on day 0 prolonged the cored on days life of all the infected mice by 6 days in comparison with untreated mice (data not shown), which delineates the opti- mal spacing of two-dose or three-dose treatment schedules. The effect of a single treatment given on day 0 diminished by day 10 and thereafter (Fig. 2) ; therefore, to minimize the risk of death, the interval between treatments should not exceed 10 *:-, 5 days. Furthermore, the timing of the first treatment relative to the viral challenge determined the required timing for administration of the second and third doses of poly(ICLC) (Fig. 3) . If the first treatment was close to the viral challenge time, the second treatment could be delayed. The reverse was true only if a third dose was administered, because giving the second treatment close to viral challenge did not provide prolonged protection. Determination of the minimal effective dose. To avoid possible toxic complications with a dose of 20 jig of poly(ICLC), the minimal effective dose was determined by administering poly(ICLC) on two schedules (Fig. 4) multiple-dose drug treatment schedule is very tedious unless the optimal schedule can be estimated with the help of a statistical model. Even though a single dose of poly(ICLC) given prior to viral challenge was sufficient to protect 40% of the infected mice, this effect diminished when the time interval between treatment and challenge was increased. Nevertheless, increased survival time was observed even when a single dose of the compound was administered 5 days before RVFV challenge.
By using single treatments between days -5 and +3, we obtained a functional relationship between time of treatment and survival that was most apparent on days 6 and 10 ( Fig.  2) Poly(ICLC) is well tolerated in mice. In 20-g male and female Swiss-Webster mice, the 50% lethal dose for a single dose was 20 and 18 mg/kg, respectively (H. Levy, unpublished data). In the present study, the highest dose tested was 0.8 mg/kg. Prophylactically, as little as 1 ,ig of poly(ICLC) per mouse, equivalent to 40 jig/kg, was effective against RVFV infection. A dose of 0.5 jig was less effective, although when it was administered three times a substantial number of the treated mice were protected from lethal RVFV infection (M. Kende, unpublished observation). Therefore, the minimal effective dose in this virus-host model is 1 jig per mouse. In comparison with 20 ,ug of poly(ICLC) per mouse, 1 jig induced 10 times less interferon (Kende et al., in preparation). In other studies, it was shown that 1 jig of poly(ICLC) was as effective as 20 jig in stimulating natural killer cells and macrophage cytotoxic activity (13) . These cell-mediated activities have a potential role in inducing an antiviral state. The antiviral efficacy of a low dose of poly(ICLC) renders this compound a prime candidate for human use, particularly because of its broad spectrum of activity. The use of a broad-spectrum antiviral drug is advantageous when the identity of the virus is unknown or when the properties of the virus are altered and fast intervention is critical for survival, although under these circumstances, such use will be limited to unique military situations. It is conceivable that prophylactic antiviral immunity can be maintained with poly(ICLC) for a long period of time by administering the compound at 5-to 6-day intervals, thereby continuously protecting humans against a potential viral threat. While poly(ICLC) at higher doses can exert significant undesirable side effects in humans (6), doses analogous to 1 jig per mouse have been safely administered for the treatment of multiple sclerosis (10) . Assessment of the minimal effective dose of poly(ICLC) in large groups of patients with multiple sclerosis is in progress (A. Salazar, personal communication).
